image
Healthcare - Medical - Devices - NASDAQ - US
$ 12.64
1.36 %
$ 556 M
Market Cap
-38.3
P/E
1. INTRINSIC VALUE

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed.[ Read More ]

The intrinsic value of one AXGN stock under the base case scenario is HIDDEN Compared to the current market price of 12.6 USD, AxoGen, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AXGN

image
FINANCIALS
159 M REVENUE
14.74%
-21.5 M OPERATING INCOME
27.75%
-21.7 M NET INCOME
24.98%
-5.72 M OPERATING CASH FLOW
64.42%
19.3 M INVESTING CASH FLOW
701.66%
1.95 M FINANCING CASH FLOW
8.92%
48.6 M REVENUE
1.53%
-316 K OPERATING INCOME
26.17%
-1.86 M NET INCOME
3.28%
3.9 M OPERATING CASH FLOW
-6.34%
-5 M INVESTING CASH FLOW
-305.52%
572 K FINANCING CASH FLOW
5.15%
Balance Sheet Decomposition AxoGen, Inc.
image
Current Assets 88 M
Cash & Short-Term Investments 37 M
Receivables 25.1 M
Other Current Assets 25.8 M
Non-Current Assets 109 M
Long-Term Investments 0
PP&E 104 M
Other Non-Current Assets 4.53 M
Current Liabilities 30.4 M
Accounts Payable 11.8 M
Short-Term Debt 1.55 M
Other Current Liabilities 17.1 M
Non-Current Liabilities 70.7 M
Long-Term Debt 67.7 M
Other Non-Current Liabilities 2.99 M
EFFICIENCY
Earnings Waterfall AxoGen, Inc.
image
Revenue 159 M
Cost Of Revenue 31.1 M
Gross Profit 128 M
Operating Expenses 149 M
Operating Income -21.5 M
Other Expenses 254 K
Net Income -21.7 M
RATIOS
80.42% GROSS MARGIN
80.42%
-13.50% OPERATING MARGIN
-13.50%
-13.66% NET MARGIN
-13.66%
-22.70% ROE
-22.70%
-11.03% ROA
-11.03%
-15.09% ROIC
-15.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AxoGen, Inc.
image
Net Income -21.7 M
Depreciation & Amortization 5.55 M
Capital Expenditures -14.9 M
Stock-Based Compensation 14.4 M
Change in Working Capital -10.9 M
Others -3.97 M
Free Cash Flow -20.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AxoGen, Inc.
image
AXGN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AxoGen, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
981 K USD 5
9-12 MONTHS
93.8 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7 months ago
Mar 21, 2024
Sell 24.3 K USD
Zaderej Karen L.
CEO
- 3166
7.68 USD
7 months ago
Mar 21, 2024
Sell 23.7 K USD
Zaderej Karen L.
CEO
- 3086
7.68 USD
7 months ago
Mar 21, 2024
Sell 254 K USD
Zaderej Karen L.
CEO
- 33028
7.68 USD
7 months ago
Mar 21, 2024
Sell 24.1 K USD
DeVinney Erick Wayne
Chief Innovation Officer
- 3141
7.68 USD
7 months ago
Mar 21, 2024
Sell 5.54 K USD
DeVinney Erick Wayne
Chief Innovation Officer
- 721
7.68 USD
7 months ago
Mar 21, 2024
Sell 5.5 K USD
DeVinney Erick Wayne
Chief Innovation Officer
- 716
7.68 USD
7 months ago
Mar 21, 2024
Sell 4.68 K USD
Scopelianos Angelo
Chief R&D Officer
- 610
7.68 USD
7 months ago
Mar 21, 2024
Sell 7.83 K USD
Scopelianos Angelo
Chief R&D Officer
- 1020
7.68 USD
7 months ago
Mar 21, 2024
Sell 40.3 K USD
Scopelianos Angelo
Chief R&D Officer
- 5251
7.68 USD
7 months ago
Mar 21, 2024
Sell 35.3 K USD
Donovan Michael Patrick
VP Operations
- 4596
7.68 USD
7 months ago
Mar 21, 2024
Sell 5.54 K USD
Donovan Michael Patrick
VP Operations
- 721
7.68 USD
7 months ago
Mar 21, 2024
Sell 5.5 K USD
Donovan Michael Patrick
VP Operations
- 716
7.68 USD
8 months ago
Mar 07, 2024
Sell 320 K USD
Donovan Michael Patrick
VP Operations
- 36310
8.81 USD
8 months ago
Mar 07, 2024
Sell 225 K USD
Freitag Gregory Gene
Director
- 25000
9 USD
11 months ago
Dec 11, 2023
Sell 10.6 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 1410
7.52 USD
11 months ago
Dec 11, 2023
Sell 23.4 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 3120
7.51 USD
11 months ago
Dec 11, 2023
Sell 59.8 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 7970
7.5 USD
1 year ago
Sep 06, 2023
Bought 62.2 K USD
Wendell Amy McBride
Director
+ 10000
6.224 USD
1 year ago
Aug 23, 2023
Bought 65.6 K USD
Burke William P. Mr.
Director
+ 10000
6.56 USD
1 year ago
Aug 16, 2023
Bought 61.1 K USD
NEELS GUIDO J
Director
+ 10000
6.11 USD
1 year ago
Jun 01, 2023
Sell 108 K USD
Freitag Gregory Gene
Director
- 12500
8.65 USD
1 year ago
Jun 01, 2023
Sell 258 K USD
Freitag Gregory Gene
Director
- 29480
8.74 USD
1 year ago
May 23, 2023
Sell 25.9 K USD
Freitag Gregory Gene
Director
- 2828
9.17 USD
1 year ago
May 23, 2023
Sell 43 K USD
Freitag Gregory Gene
Director
- 4640
9.26 USD
1 year ago
Feb 01, 2023
Sell 136 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 14550
9.36 USD
1 year ago
Jan 31, 2023
Sell 137 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 14320
9.55 USD
1 year ago
Jan 30, 2023
Sell 137 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 14111
9.69 USD
1 year ago
Jan 27, 2023
Sell 213 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 20940
10.16 USD
2 years ago
Nov 16, 2022
Sell 127 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 10649
11.88 USD
2 years ago
Nov 14, 2022
Sell 166 K USD
Freitag Gregory Gene
Director
- 13000
12.74 USD
2 years ago
Nov 08, 2022
Sell 162 K USD
Freitag Gregory Gene
Director
- 13000
12.5 USD
2 years ago
Aug 10, 2022
Sell 86.2 K USD
Freitag Gregory Gene
director:
- 8886
9.696 USD
2 years ago
Aug 04, 2022
Sell 255 K USD
Freitag Gregory Gene
Director
- 24000
10.64 USD
2 years ago
Aug 04, 2022
Sell 135 K USD
Freitag Gregory Gene
director:
- 13046
10.37 USD
3 years ago
Aug 06, 2021
Sell 272 K USD
Zaderej Karen L.
CEO
- 14756
18.4 USD
3 years ago
Aug 06, 2021
Sell 24.1 K USD
Zaderej Karen L.
CEO
- 1259
19.18 USD
3 years ago
Aug 06, 2021
Sell 422 K USD
Zaderej Karen L.
CEO
- 22902
18.41 USD
3 years ago
Aug 06, 2021
Sell 39.9 K USD
Zaderej Karen L.
CEO
- 2083
19.16 USD
3 years ago
Jul 21, 2021
Sell 38.8 K USD
Donovan Michael Patrick
VP Operations
- 1935
20.04 USD
3 years ago
Jun 04, 2021
Sell 50 K USD
MARTINEZ MARIA D.
Chief Human Resources Officer
- 2652
18.86 USD
3 years ago
Feb 25, 2021
Sell 529 K USD
Freitag Gregory Gene
Director
- 24000
22.06 USD
3 years ago
Feb 18, 2021
Sell 34.6 K USD
Donovan Michael Patrick
VP Operations
- 1808
19.15 USD
3 years ago
Jan 08, 2021
Sell 1.3 M USD
Zaderej Karen L.
CEO
- 65000
20 USD
3 years ago
Dec 30, 2020
Sell 30.3 K USD
Donovan Michael Patrick
VP Operations
- 1733
17.48 USD
3 years ago
Dec 29, 2020
Sell 6.61 K USD
DeVinney Erick Wayne
VP, Clinical&Translational Sc
- 371
17.81 USD
3 years ago
Dec 29, 2020
Sell 10.1 K USD
Donovan Michael Patrick
VP Operations
- 567
17.81 USD
3 years ago
Dec 29, 2020
Sell 16.3 K USD
Freitag Gregory Gene
Director
- 916
17.81 USD
3 years ago
Dec 29, 2020
Sell 23 K USD
MARIANI PETER J
Chief Financial Officer
- 1293
17.81 USD
3 years ago
Dec 29, 2020
Sell 10.1 K USD
Scopelianos Angelo
VP Research & Development
- 567
17.81 USD
3 years ago
Dec 29, 2020
Sell 62.3 K USD
Zaderej Karen L.
CEO
- 3500
17.81 USD
3 years ago
Dec 29, 2020
Sell 10.1 K USD
Friedman Mark Louis
VP,Regulatory & Quality
- 567
17.81 USD
3 years ago
Dec 29, 2020
Sell 10.1 K USD
MARTINEZ MARIA D.
Chief Human Resources Officer
- 567
17.81 USD
3 years ago
Dec 29, 2020
Sell 11.6 K USD
Billet Isabelle
Chief Strategy and BD Officer
- 649
17.81 USD
3 years ago
Dec 22, 2020
Sell 4.8 K USD
Donovan Michael Patrick
VP Operations
- 279
17.19 USD
3 years ago
Dec 21, 2020
Sell 20.9 K USD
Zaderej Karen L.
CEO
- 1275
16.42 USD
3 years ago
Dec 21, 2020
Sell 2.41 K USD
DeVinney Erick Wayne
VP, Clinical&Translational Sc
- 147
16.42 USD
3 years ago
Dec 21, 2020
Sell 6.22 K USD
Freitag Gregory Gene
Director
- 379
16.42 USD
3 years ago
Dec 21, 2020
Sell 1.58 K USD
Donovan Michael Patrick
VP Operations
- 96
16.42 USD
3 years ago
Dec 21, 2020
Sell 7.9 K USD
MARIANI PETER J
Chief Financial Officer
- 481
16.42 USD
3 years ago
Dec 21, 2020
Sell 1.58 K USD
Friedman Mark Louis
VP,Regulatory & Quality
- 96
16.42 USD
7. News
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer. seekingalpha.com - 1 week ago
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 1 month ago
First September Gains in 5 Years? Buy 3 Breakout Stocks Now Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today. zacks.com - 1 month ago
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. globenewswire.com - 2 months ago
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 months ago
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2 months ago
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2 months ago
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 months ago
Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports 2024 Second Quarter Financial Results Call. At this time all participants are in a listen-only mode. seekingalpha.com - 3 months ago
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago. zacks.com - 3 months ago
Axogen, Inc. Announces New Leadership Appointments ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months. globenewswire.com - 3 months ago
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
8. Profile Summary

AxoGen, Inc. AXGN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 556 M
Dividend Yield 0.00%
Description AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Contact 13631 Progress Boulevard, Alachua, FL, 32615 https://www.axogeninc.com
IPO Date Dec. 17, 1986
Employees 426
Officers Mr. Jens Schroeder Kemp Chief Marketing Officer Ms. Karen Zaderej Advisor Mr. Harold D. Tamayo Vice President of Finance & Investor Relations Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer Mr. Erick DeVinney Chief Innovation Officer Ms. Doris Quackenbush Vice President of Sales Mr. Marc A. Began Executive Vice President, General Counsel & Chief Compliance Officer Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A. Chief Financial Officer Mr. Todd Puckett Vice President of Operations